TY - JOUR
T1 - Expression of interleukin-17F in a mouse model of allergic asthma
AU - Suzuki, Shintaro
AU - Kokubu, Fumio
AU - Kawaguchi, Mio
AU - Homma, Tetsuya
AU - Odaka, Miho
AU - Watanabe, Shin
AU - Ieki, Koshi
AU - Matsukura, Satoshi
AU - Kurokawa, Masatsugu
AU - Takeuchi, Hiroko
AU - Sasaki, Yoshiko
AU - Huang, Shau Ku
AU - Adachi, Mitsuru
AU - Ota, Hidekazu
PY - 2007/6
Y1 - 2007/6
N2 - Background: Interleukin (IL)-17F is a recently discovered cytokine and is derived from a panel of limited cell types, such as activated CD4+ T cells, basophils, and mast cells. IL-17F is known to induce several cytokines and chemokines. However, its involvement in airway inflammation has not been well understood. To this end, the expression of IL-17F and the inhibitory effects of glucocorticoids on its expression in a mouse model of asthma were examined. Methods: Five-week-old BALB/c male mice were sensitized by intraperitoneal injection (i.p.) of ovalbumin (OVA) with alum, and challenged by daily inhalation of aerosolized 1% OVA. 24 h after last challenge (OVA/OVA), the expression of IL-17F was examined in lung tissues by immunohistochemistry and reverse-transcription polymerase chain reaction. Control mice were sensitized and challenged with saline (Sham/Sham). In addition, a group of OVA-sensitized mice received i.p. injection of water-soluble dexamethasone (DEX) in saline 1 h before OVA challenge (OVA/DEX). Results: In sham-challenged mice, IL-17F was not expressed in the lungs, while, in contrast, IL-17F was predominantly expressed in bronchial epithelial cells in addition to the infiltrating inflammatory cells in OVA/OVA mice. Further, the expression of IL-17 F was significantly attenuated by the treatment of mice with DEX. Conclusion: These results suggest that bronchial epithelium-derived IL-17F may represent a new pharmacological target for glucocorticoids and may play a role in allergic asthma.
AB - Background: Interleukin (IL)-17F is a recently discovered cytokine and is derived from a panel of limited cell types, such as activated CD4+ T cells, basophils, and mast cells. IL-17F is known to induce several cytokines and chemokines. However, its involvement in airway inflammation has not been well understood. To this end, the expression of IL-17F and the inhibitory effects of glucocorticoids on its expression in a mouse model of asthma were examined. Methods: Five-week-old BALB/c male mice were sensitized by intraperitoneal injection (i.p.) of ovalbumin (OVA) with alum, and challenged by daily inhalation of aerosolized 1% OVA. 24 h after last challenge (OVA/OVA), the expression of IL-17F was examined in lung tissues by immunohistochemistry and reverse-transcription polymerase chain reaction. Control mice were sensitized and challenged with saline (Sham/Sham). In addition, a group of OVA-sensitized mice received i.p. injection of water-soluble dexamethasone (DEX) in saline 1 h before OVA challenge (OVA/DEX). Results: In sham-challenged mice, IL-17F was not expressed in the lungs, while, in contrast, IL-17F was predominantly expressed in bronchial epithelial cells in addition to the infiltrating inflammatory cells in OVA/OVA mice. Further, the expression of IL-17 F was significantly attenuated by the treatment of mice with DEX. Conclusion: These results suggest that bronchial epithelium-derived IL-17F may represent a new pharmacological target for glucocorticoids and may play a role in allergic asthma.
KW - Bronchial asthma
KW - Glucocorticoids
KW - Interleukin-17F
UR - https://www.scopus.com/pages/publications/34249822228
UR - https://www.scopus.com/pages/publications/34249822228#tab=citedBy
U2 - 10.1159/000101413
DO - 10.1159/000101413
M3 - Article
C2 - 17541285
AN - SCOPUS:34249822228
SN - 1018-2438
VL - 143
SP - 89
EP - 94
JO - International Archives of Allergy and Immunology
JF - International Archives of Allergy and Immunology
IS - SUPPL. 1
ER -
